Latest News

enGene Snags FDA RMAT Designation for Bladder Cancer Gene Therapy Detalimogene
enGene Snags FDA RMAT Designation for Bladder Cancer Gene Therapy Detalimogene

June 25th 2025

The gene therapy is currently being evaluated in the phase 1/2 LEGEND clinical trial.

Around the Helix: Cell and Gene Therapy Company Updates – June 25, 2025
Around the Helix: Cell and Gene Therapy Company Updates – June 25, 2025

June 25th 2025

FDA Announces Investigation of Deaths Following Treatment With Sarepta’s DMD Gene Therapy Elevidys
FDA Announces Investigation of Deaths Following Treatment With Sarepta’s DMD Gene Therapy Elevidys

June 25th 2025

Tami John, MD
Tami John, MD, on Barriers to Access for Gene Therapy in β-Thalassemia

June 24th 2025

Linda Marbán, PhD, the CEO of Capricor Therapeutics
FDA Indicates AdComm Not Currently Required for Capricor’s BLA for DMD Cardiomyopathy Cell Therapy Deramiocel

June 24th 2025

Video Interviews

Conference Coverage

View All
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Exploring DARIC CAR T-Cells for Autoimmune Indications

June 23rd 2025

Brian Kim, MBA, the chief executive officer of Mission Bio
The Emergence of CRISPR-Based Medicines and the Resurgence of AAV

June 22nd 2025

Vertex’s Islet Cell Therapy Zimislecel (VX-880) Restores Endogenous Insulin Secretion in Type 1 Diabetes
Vertex’s Islet Cell Therapy Zimislecel (VX-880) Restores Endogenous Insulin Secretion in Type 1 Diabetes

June 20th 2025

Brian Kim, MBA, the chief executive officer of Mission Bio
Multiomic Single-Cell Sequencing and the Ebbs and Flows of the Gene Therapy Field

June 19th 2025

All News

© 2025 MJH Life Sciences

All rights reserved.